Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

In this case report, azathioprine was linked to anagen effluvium in a 36-year-old woman after two weeks of use; hair regrowth occurred once the drug was stopped and minoxidil treatment was started.

This study found that nanostructured lipid carriers could serve as a promising vehicle for topical Acitretin delivery in psoriasis treatment, potentially reducing oral side effects and enhancing patient compliance.

This study identified a compound heterozygous mutation in a hairless rhesus macaque, which was associated with skin abnormalities similar to those in hairless mice and humans with APL.

In this study, 95% of cancer patients undergoing chemotherapy at Ocean Road Cancer Institute experienced adverse drug reactions, with early symptoms including fatigue, nausea, and loss of appetite.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study identified orally available itaconate derivatives that improve cellular permeability and bioavailability, with specific POC-based prodrugs showing significant inhibition of inflammatory cytokines in human epidermal keratinocytes and favorable oral pharmacokinetics, highlighting their potential for treating systemic and skin disorders.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

This systematic review synthesizes the current state of drug repurposing, revealing its potential in various therapeutic areas like oncology and infectious diseases through insights from mechanistic studies and real-world evidence, and discusses emerging tools and challenges in the field.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.

This study demonstrated that a microarray patch can deliver antibodies in a controlled and prolonged manner, maintaining their functionality after manufacturing and heat exposure, with successful pharmacokinetic proof-of-concept in rats.

This study observed that melatonin treatment reduced cellular damage and apoptosis in the intestinal epithelium of rats with acute necrotizing pancreatitis compared to untreated rats.

This study introduced a pH-responsive polymeric wound dressing that enhances healing in chronic wounds by changing shape and drug delivery based on wound pH, achieving a 94.88% healing rate in diabetic mice by day 14.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This review highlights the dual nature of Abrus precatorius Linn., known for its toxic compound abrin and medicinal potential. The research emphasizes its traditional uses, phytochemical diversity, and pharmacological effects, while calling for standardization and controlled trials to ensure safety and efficacy in therapeutic applications.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

This review discusses the concept of drug repositioning and highlights fragmin and protamine as emerging biomaterials for tissue engineering and regenerative medicine, but it reports no new clinical results.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

In this study, injecting platelet-rich plasma into the muscular layer of the intestinal wall in rabbits significantly reduced adhesion development compared to soaking methods, suggesting an improvement in anastomosis regeneration.

In this study, a synthetic antagonist of the p75 neurotrophin receptor was found to significantly inhibit hair follicle regression in murine skin cultures, suggesting a potential role in treating hair disorders characterized by premature catagen entry.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.